Results of Phase III Clinical Trial: a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Direkord in Ischemic Stroke Patients in Early Recovery Period
-
Published:2023-12-06
Issue:4
Volume:19
Page:81-93
-
ISSN:2713-0428
-
Container-title:Journal Biomed
-
language:
-
Short-container-title:BIOMEDICINE
Author:
Pomytkin I. A.1, Pisarev V. V.2, Merkulov M. E.2, Lukinykh L. V.3, Morzhukhina M. V.4, Karkischenko N. N.1
Affiliation:
1. Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia 2. Scientific and Production Center Probiotech 3. Vsevolozhsk Clinical Interdistrict Hospital 4. Yaroslavl Clinical Hospital No. 2
Abstract
Direkord is an original drug containing the active substance of dicholine succinate, which improves the sensitivity of insulin receptors in neurons to insulin. The aim of this work was to evaluate the efficacy and safety of the drug in ischemic stroke patients in the early recovery period. In total, 160 patients after the first ischemic stroke in the carotid system, confirmed by computed or magnetic resonance imaging, with a stroke duration from 3 weeks to 2 months, mean age 63.2±8.4 years, were randomized into two treatment groups. The first group (n=80) received Direkord intramuscularly at a dose of 600 mg/day for two weeks; the second group (n=80) received a placebo. Treatment response was defined as an improvement in neurological status, functional status, and cognitive function of the patients: at least a two-fold decrease in the total NIHSS score, the total Barthel score ≥ 95, and the total MoCA score ≥ 26. The analysis of the primary endpoint of the study using exact Fisher’s test showed that Direkord was statistically significantly superior to the placebo (p=0.017) in the number of patients who responded to the therapy — 23.7 and 8.7% of patients in groups, respectively. The secondary end point analysis revealed a statistically significant superiority of Direkord over the placebo in reducing neurological deficits on the NIHSS scale (p=0.004), on the Rankin scale (p=0.0357), and on the CGI-I (p<0.001) and PGI-I (p<0.001) global clinical impression scales. Direkord has a good safety profile; thus, no statistically significant differences were found with the placebo in any of the safety parameters, including the number of adverse events, vital signs, laboratory parameters, and ECG. Overall, Direkord is statistically significantly more effective than placebo in recovering function and daily activities after ischemic stroke.
Publisher
Scientific Center for Biomedical Technologies of the Federal Medical-Biological Agency
Reference14 articles.
1. Åberg D., Åberg N.D., Jood K., Holmegaard L., Redfors P., Blomstrand C., Isgaard J., Jern C., Svensson J. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients — a prospective observational study. BMC Neurol. 2019;19(1):177. DOI: 10.1186/s12883-019-1406-3. 2. Ago T., Matsuo R., Hata J., Wakisaka Y., Kuroda J., Kitazono T., Kamouchi M. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):1470–e1477. DOI: 10.1212/WNL.0000000000005358. 3. Jing J., Pan Y., Zhao X., Zheng H., Jia Q., Mi D., Chen W., Li H., Liu L., Wang C., He Y., Wang D., Wang Y., Wang Y. Insulin Resistance and Prognosis of Nondiabetic Patients with Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regulation in Patients with Acute Stroke Across China). Stroke. 2017;48(4):887–893. DOI: 10.1161/STROKEAHA.116.015613. 4. Joy M.T., Carmichael S.T. Encouraging an excitable brain state: mechanisms of brain repair in stroke. Nat. Rev. Neurosci. 2021;22(1):38–53. DOI: 10.1038/s41583-020-00396-7. 5. Kernan W.N., Viscoli C.M., Furie K.L., Young L.H., Inzucchi S.E., Gorman M., Guarino P.D., Lovejoy A.M., Peduzzi P.N., Conwit R., Brass L.M., Schwartz G.G., Adams H.P. Jr, Berger L., Carolei A., Clark W., Coull B., Ford G.A., Kleindorfer D., O'Leary J.R., Parsons M.W., Ringleb P., Sen S., Spence J.D., Tanne D., Wang D., Winder T.R.; IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N. Engl. J. Med. 2016;374(14):1321– 1331. DOI: 10.1056/NEJMoa1506930.
|
|